Karuna Positive Results on Phase 3 EMERGENT-3 Trial of KarXT
CenExel is proud to announce that the work of David Walling, PhD, CEO and Principal Investigator at CenExel CNS, joined lead author, John H Krystal, as co-author of the
View More The Placebo-Control Reminder Script and Supplementary Instrument Properties
CenExel is proud to highlight the poster presented at the International Society for CNS Clinical Trials and Methodology (ISCTM) Annual Scientific Meeting, February 2023, Washington, DC. ABSTRACT Introduction: The
View More Emraclidine for the treatment of schizophrenia
CenExel is proud to announce that the work of David Walling, PhD, CEO and Principal Investigator at CenExel CNS, joined lead author, John H Krystal, as co-author of the
View More Primer on the Autonomic Nervous System
This book provides a concise and accessible overview of autonomic neuroscience for students, scientists, and clinicians.
View More
CenExel CNS Opens Center in Los Alamitos, California
[et_pb_section fb_built=”1″ _builder_version=”4.12.0″ global_colors_info=”{}”][et_pb_row _builder_version=”4.12.0″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.12.0″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″] Los Alamitos, November 29, 2022 /GlobeNewswire/ — CenExel
View More Validation of a suite of ERP and QEEG biomarkers
Validation of a suite of ERP and QEEG biomarkers in a pre-competitive, industry led-study in subjects with schizophrenia and healthy volunteers.
View More PCRS: Essential Perspectives from the End User
CenExel is proud to highlight the poster presented at the Annual CNS Summit, November 2022, Boca Raton, FL. ABSTRACT Introduction: Placebo and nocebo responses continue to hinder potential treatment
View More CenExel Acquires Apex Innovative Sciences
[et_pb_section fb_built=”1″ _builder_version=”4.12.0″ global_colors_info=”{}”][et_pb_row _builder_version=”4.12.0″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.12.0″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”] Salt Lake City, June 16, 2022 /GlobeNewswire/ — CenExel announces
View More Enhancing Patient Retention in ADHD studies
CenExel is proud to highlight the poster presented at the Annual Meeting of the American Society of Clinical Psychopharmacology (ASCP), May 2022, Scottsdale, AZ. ABSTRACT Introduction: Reducing study participant
View More Retention in Schizophrenia and Schizoaffective Disorder Studies
CenExel is proud to highlight the poster presented at the Schizophrenia International Research Society (SIRS) Annual Scientific Meeting, April 2022, Florence Italy. ABSTRACT Background: Clinical trials focusing on psychosis
View More
